February 1, 2005 -- Since last week Monday, the Centient Biotech 200 has climbed 187 points to 3418, a 5.8% bounce. For five out of the last six trading sessions, biotech has moved higher--and it lost only 2 points on the sixth day. Today, in a market that was higher for the entire session, the Centient Biotech 200 moved up 34.31 points to 3418.37, a rise of 1.01%. Sequenom took off after announcing it identified a second breast cancer gene, Aastrom passed an FDA stem-cell safety test, StemCells was told to submit more info before taking its stem cell product into the clinic, Protein Design Labs upped its purchase price of ESP by $25 million, and Nastech won FDA approval for a vitamin B-12 nasal spray. We discuss all these events...
